In lat­est set­back for sol­id tu­mor CAR-T, Celyad paus­es tri­al fol­low­ing two pa­tient deaths

Ef­forts to push CAR-T ther­a­py, so ef­fec­tive in many blood can­cers, in­to sol­id tu­mors took an­oth­er hit Mon­day, af­ter Celyad On­col­o­gy an­nounced that two pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER